financetom
Business
financetom
/
Business
/
BXP Q1 FFO Declines, Revenue Increases; Guides Q2 FFO Below Consensus View
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BXP Q1 FFO Declines, Revenue Increases; Guides Q2 FFO Below Consensus View
May 25, 2025 9:17 PM

05:08 PM EDT, 04/29/2025 (MT Newswires) -- BXP (BXP) reported Q1 funds from operations late Tuesday of $1.64 per diluted share, down from $1.73 a year earlier.

Analysts polled by FactSet expected $1.65.

Revenue for the quarter ended March 31 was $865.2 million, up from $839.4 million a year earlier.

Analysts polled by FactSet expected $835.8 million.

For Q2, the real estate investment trust is projecting FFO of $1.65 to $1.67. Analysts polled by FactSet are looking for $1.70.

For 2025, the company is projecting FFO of $6.80 to $6.92. Analysts polled by FactSet are expecting $6.90.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Novo Nordisk Plans First Bond Sale in 2 Years
Market Chatter: Novo Nordisk Plans First Bond Sale in 2 Years
May 13, 2024
08:47 AM EDT, 05/13/2024 (MT Newswires) -- Novo Nordisk A/S ( NVO ) , through its finance subsidiary in the Netherlands, has hired banks to help it issue euro-nominated bonds in a benchmark offering with 2- to 10-year maturities, Bloomberg reported, citing a person familiar with the matter. Proceeds would be used for general corporate purposes, including financing its Catalent...
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment
May 13, 2024
08:45 AM EDT, 05/13/2024 (MT Newswires) -- Fulcrum Therapeutics ( FULC ) said Monday it has signed a deal with Sanofi ( SNY ) for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD). Under the terms of the deal, Sanofi ( SNY ) will have exclusive rights to commercialize losmapimod outside the US, while Fulcrum retains US rights, Fulcrum said. The...
Booking Designated as a Gatekeeper Under EU Digital Markets Act
Booking Designated as a Gatekeeper Under EU Digital Markets Act
May 13, 2024
08:46 AM EDT, 05/13/2024 (MT Newswires) -- Booking Holdings ( BKNG ) has been designated by the European Commission as a gatekeeper under the Digital Markets Act (DMA), the Commission said Monday. As a result, Booking has six months to submit a detailed compliance report outlining how it complies with each of the DMA's obligations, the Commission said. If Booking...
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro
May 13, 2024
08:51 AM EDT, 05/13/2024 (MT Newswires) -- Zai Lab ( ZLAB ) said late Sunday the New Drug Application for Augtyro has received approval from China's National Medical Products Administration. Approval of the application is based on results of a phase 1/2 trial that assessed Augtyro in TKI-naive and TKI-pretreated patients, the company said. The regulator accepted the application for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved